Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Use of Direct Oral Anticoagulants in Children and Adolescents.

Albisetti M.

Hamostaseologie. 2020 Feb;40(1):64-73. doi: 10.1055/s-0039-3400491. Epub 2020 Feb 12.

PMID:
32050291
2.

Single Ventricle Physiology Patients and Coagulation Abnormalities: Is There a Relationship With Hemodynamic Data and Postoperative Course? A Pilot Study.

Callegari A, Christmann M, Albisetti M, Kretschmar O, Quandt D.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619888695. doi: 10.1177/1076029619888695.

PMID:
31822112
3.

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

Brandao LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M.

Blood. 2019 Dec 5. pii: blood.2019000998. doi: 10.1182/blood.2019000998. [Epub ahead of print]

4.

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators.

Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13.

PMID:
31420317
5.

Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories.

Haemophilia. 2019 Jul;25(4):708-717. doi: 10.1111/hae.13763. Epub 2019 May 20.

6.

Official communication of the SSC: Recommendations for future research in catheter-related arterial thrombosis in children.

Albisetti M, Rizzi M, Bonduel M, Revel-Vilk S, Goldenberg N; Pediatric and Neonatal Thrombosis and Haemostasis Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Res Pract Thromb Haemost. 2019 Jan 15;3(2):193-196. doi: 10.1002/rth2.12179. eCollection 2019 Apr.

7.

Unplanned Return Visits to a Pediatric Emergency Department.

Seiler M, Furrer PR, Staubli G, Albisetti M.

Pediatr Emerg Care. 2019 Mar 1. doi: 10.1097/PEC.0000000000001764. [Epub ahead of print]

PMID:
30829838
8.

Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.

Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, Gropper S, Halton JML, Harper R, Huang F, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Brandão LR.

Res Pract Thromb Haemost. 2018 Apr 24;2(3):580-590. doi: 10.1002/rth2.12093. eCollection 2018 Jul.

9.

Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.

Albisetti M, Biss B, Bomgaars L, Brandão LR, Brueckmann M, Chalmers E, Gropper S, Harper R, Huang F, Luciani M, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Halton JML.

Res Pract Thromb Haemost. 2018 Mar 25;2(2):347-356. doi: 10.1002/rth2.12086. eCollection 2018 Apr.

10.

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.

Albisetti M, Schlosser A, Brueckmann M, Gropper S, Glund S, Tartakovsky I, Brandão LR, Reilly PA.

Res Pract Thromb Haemost. 2017 Nov 17;2(1):69-76. doi: 10.1002/rth2.12053. eCollection 2018 Jan.

11.

Treatment of arterial thrombosis in children: Methods and mechanisms.

Rizzi M, Albisetti M.

Thromb Res. 2018 Sep;169:113-119. doi: 10.1016/j.thromres.2018.07.013. Epub 2018 Jul 6. Review.

PMID:
30032038
12.

Catheter-Related Arterial Thrombosis in Neonates and Children: A Systematic Review.

Rizzi M, Goldenberg N, Bonduel M, Revel-Vilk S, Amankwah E, Albisetti M.

Thromb Haemost. 2018 Jun;118(6):1058-1066. doi: 10.1055/s-0038-1642635. Epub 2018 Apr 25.

PMID:
29695022
13.

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.

Halton JML, Picard AC, Harper R, Huang F, Brueckmann M, Gropper S, Maas H, Tartakovsky I, Nurmeev I, Mitchell LG, Brandão LR, Chalmers E, Albisetti M.

Thromb Haemost. 2017 Nov;117(11):2168-2175. doi: 10.1160/TH17-06-0429. Epub 2017 Nov 30.

PMID:
29202215
14.

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.

Halton JML, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Gropper S, Harper R, Huang F, Luciani M, Maas H, Tartakovsky I, Mitchell LG.

J Thromb Haemost. 2017 Nov;15(11):2147-2157. doi: 10.1111/jth.13847. Epub 2017 Oct 26.

15.

Neonatal renal and inferior vena cava thrombosis associated with fetal thrombotic vasculopathy: a case report.

Giacchetti L, De Gaudenzi M, Leoncini A, Ferrucci E, Pezzoli V, Albisetti M.

J Med Case Rep. 2017 Aug 28;11(1):248. doi: 10.1186/s13256-017-1414-0.

16.

Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.

von Mackensen S, Kalnins W, Krucker J, Weiss J, Miesbach W, Albisetti M, Pabinger I, Oldenburg J.

Haemophilia. 2017 Jul;23(4):566-574. doi: 10.1111/hae.13221. Epub 2017 Mar 30.

17.

Long-Term Outcome of Catheter-Related Arterial Thrombosis in Infants with Congenital Heart Disease.

Rizzi M, Kroiss S, Kretschmar O, Forster I, Brotschi B, Albisetti M.

J Pediatr. 2016 Mar;170:181-7.e1. doi: 10.1016/j.jpeds.2015.11.024. Epub 2015 Dec 10.

PMID:
26685072
18.

Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.

Risitano AM, Marotta S, Calzone R, Grimaldi F, Zatterale A; RIAF Contributors.

Haematologica. 2016 Mar;101(3):319-27. doi: 10.3324/haematol.2015.133520. Epub 2015 Dec 3.

19.

Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants.

Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Erratum in: Thromb Haemost. 2016 Mar;115(3):684. Hollingsworth, R [Added].

20.

FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies.

Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators.

Haemophilia. 2016 Jan;22(1):e36-8. doi: 10.1111/hae.12764. Epub 2015 Jul 24. No abstract available.

PMID:
26208036

Supplemental Content

Loading ...
Support Center